Synovial Tissue Response to Treatment with TNF Blockers in Peripheral Spondyloarthritis

類似資料

• Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis
  著者:: Turina, Maureen C, 等
  出版事項: (2014)
• Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation
  著者:: Paramarta, Jacqueline E, 等
  出版事項: (2014)
• Serum biomarkers to predict clinical response in proof-of-concept trials in spondyloarthritis
  著者:: Turina, Maureen, 等
  出版事項: (2011)
• Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis
  著者:: de Winter, Janneke J, 等
  出版事項: (2019)
• Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis
  著者:: Janneke J de Winter, 等
  出版事項: (2019-06-01)